Results 151 to 160 of about 33,694 (186)
Some of the next articles are maybe not open access.
A Review of WHO International Standards for Botulinum Antitoxins
Biologicals, 2006Clostridium botulinum produces the most potent known toxins, with seven distinct serotypes currently defined (A-G). These toxins can cause a life threatening systemic toxicity whether through natural causes such as food poisoning, infant botulism, wound botulism, or through use as bio-terror agents (e.g. inhalational botulism). It was realised early on
Russell G A Jones +2 more
exaly +3 more sources
Iatrogenic Botulism: A Case Treated With Botulinum Antitoxin
Clinical Neuropharmacology, 2022Objective Botulinum toxin type A is widely used for the treatment of spasticity, focal dystonia, hemifacial spasm, hyperhidrosis, strabismus, chronic migraine, and also cosmetic purposes. Therapeutic use is commonly effective and safe.
Ozge Gonul Oner +3 more
openaire +2 more sources
Antitoxin therapy for botulinum intoxication
Reviews in Medical Microbiology, 2001Botulinum toxin is the most toxic substance known to mankind. It is involved in infant botulism, classical food-borne botulism, wound botulism, and is a threat in biological warfare or bioterrorism.
Carl N. Mayers +2 more
openaire +1 more source
Clinical Immunology, 2010
To produce a vaccine suitable for human use, a recombinant non His-tagged isoform of the Hc domain of botulinum neurotoxin serotype F (rFHc) was expressed in Escherichia coli and purified by sequential chromatography. The rFHc was evaluated as a subunit vaccine candidate in mouse model of botulism.
Yun-Zhou Yu, Wei-Yuan Yu, Zhi-Wei Sun
exaly +3 more sources
To produce a vaccine suitable for human use, a recombinant non His-tagged isoform of the Hc domain of botulinum neurotoxin serotype F (rFHc) was expressed in Escherichia coli and purified by sequential chromatography. The rFHc was evaluated as a subunit vaccine candidate in mouse model of botulism.
Yun-Zhou Yu, Wei-Yuan Yu, Zhi-Wei Sun
exaly +3 more sources
Development of an Avian Antitoxin to Type A Botulinum Neurotoxin
1993Most commercially available antitoxins and antivenoms are raised in horses and purified by bulk fractionation techniques. These preparations frequently elicit deleterious side effects that compromise their efficacy and the treatment of intoxication or envenomation.
B. S. Thalley +5 more
openaire +1 more source
An in vitro cell-based potency assay for pharmaceutical type A botulinum antitoxins
Vaccine, 2017Botulism therapy relies on passive immunization with antitoxin. The mouse neutralization test is the only pharmacopeia assay to measure the potency of antitoxin preparations. Herein, we present an in vitro cell-based assay for the measurement of pharmaceutical type A antitoxin potency. Accuracy, reproducibility and compatibility with the mouse bioassay
Amram, Torgeman +8 more
openaire +2 more sources
Biochimie, 2010
Concern about the malicious applications of botulinum neurotoxin has highlighted the need for a new generation of safe and highly potent antitoxins. In this study, we developed and evaluated the preclinical pharmacology and safety of a new F(ab')₂ antitoxin against botulinum neurotoxin serotype A (BoNT/A).
Yun-Zhou Yu, Wei-Yuan Yu, Zhi-Wei Sun
exaly +3 more sources
Concern about the malicious applications of botulinum neurotoxin has highlighted the need for a new generation of safe and highly potent antitoxins. In this study, we developed and evaluated the preclinical pharmacology and safety of a new F(ab')₂ antitoxin against botulinum neurotoxin serotype A (BoNT/A).
Yun-Zhou Yu, Wei-Yuan Yu, Zhi-Wei Sun
exaly +3 more sources
Toxicon, 2016
Japanese botulinum antitoxins have been used for more than 50 years; however, their safety and therapeutic efficacy are not clear. In order to analyze the available data on botulinum antitoxin therapy in Japan, we surveyed published reports about botulism cases in which botulinum antitoxins were used, and retrospectively analyzed the safety and ...
Keita, Mottate +9 more
openaire +2 more sources
Japanese botulinum antitoxins have been used for more than 50 years; however, their safety and therapeutic efficacy are not clear. In order to analyze the available data on botulinum antitoxin therapy in Japan, we surveyed published reports about botulism cases in which botulinum antitoxins were used, and retrospectively analyzed the safety and ...
Keita, Mottate +9 more
openaire +2 more sources
Clinical Pharmacology & Therapeutics, 1968
A diagnosis for botulism in man probably would not be made until after signs and symptoms developed. In this study the critical time for initiation of treatment was emphasized. Rhesus monkeys were given 2.5 to 5 LD50 of botulinum toxin, type A, intravenously. As soon as toxic signs were observed, therapy was initiated.
F W, Oberst +3 more
openaire +2 more sources
A diagnosis for botulism in man probably would not be made until after signs and symptoms developed. In this study the critical time for initiation of treatment was emphasized. Rhesus monkeys were given 2.5 to 5 LD50 of botulinum toxin, type A, intravenously. As soon as toxic signs were observed, therapy was initiated.
F W, Oberst +3 more
openaire +2 more sources
In vitro assays for botulinum toxin and antitoxins.
Developments in biological standardization, 1987Clostridium botulinum produces several powerful neuroparalytic toxins which, although rare in food-poisoning instances, are generally fatal. A considerable amount of effort has therefore been made by the food industry to ensure that food treatment processes adequate to prevent growth and toxin production by Cl. botulinum.
C, Shone +6 more
openaire +1 more source